Casgevy Momentum + Pipeline News: Why CRISPR Therapeutics Could Break Out in 2026
CRISPR Therapeutics (CRSP) has moved from concept to commercial product with Casgevy and is reporting accelerating revenue and patient initiations. Balance-sheet strength and upcoming 2026 commercial / clinical catalysts make a breakout plausible. This trade idea lays out an actionable long with entry at $45.00, stop at $34.00 and a target at $78.4…